FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

A correction has been published: N Engl J Med 2001;345(23):1716.

Previous Volume 345:494-502 August 16, 2001 Number 7 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article Related Article PubMed Citation

ABSTRACT

Background Despite current treatments, patients who have acute coronary syndromes without ST-segment elevation have high rates of major vascular events. We evaluated the efficacy and safety of the antiplatelet agent clopidogrel when given with aspirin in such patients.

Methods We randomly assigned 12,562 patients who had presented within 24 hours after the onset of symptoms to receive clopidogrel (300 mg immediately, followed by 75 mg once daily) (6259 patients) or placebo (6303 patients) in addition to aspirin for 3 to 12 months.

Results The first primary outcome — a composite of death from cardiovascular causes, nonfatal myocardial infarction, or stroke — occurred in 9.3 percent of the patients in the clopidogrel group and 11.4 percent of the patients in the placebo group (relative risk with clopidogrel as compared with placebo, 0.80; 95 percent confidence interval, 0.72 to 0.90; P<0.001). The second primary outcome — the first primary outcome or refractory ischemia — occurred in 16.5 percent of the patients in the clopidogrel group and 18.8 percent of the patients in the placebo group (relative risk, 0.86, P<0.001). The percentages of patients with in-hospital refractory or severe ischemia, heart failure, and revascularization procedures were also significantly lower with clopidogrel. There were significantly more patients with major bleeding in the clopidogrel group than in the placebo group (3.7 percent vs. 2.7 percent; relative risk, 1.38; P=0.001), but there were not significantly more patients with episodes of life-threatening bleeding (2.1 percent vs. 1.8 percent, P=0.13) or hemorrhagic strokes.

Conclusions The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation. However, the risk of major bleeding is increased among patients treated with clopidogrel.

Source Information

The Manuscript Writing Committee (Salim Yusuf, D.Phil., F.R.C.P.C., Feng Zhao, M.Sc., Shamir R. Mehta, M.D., F.R.C.P.C., Susan Chrolavicius, B.Sc., Gianni Tognoni, M.D., and Keith K. Fox, M.D., F.R.C.P.) assumes responsibility for the overall content of the manuscript.

Address reprint requests to Dr. Yusuf at the Canadian Cardiovascular Collaboration Project Office, Population Health Research Institute, McMaster University, Hamilton General Hospital, 237 Barton St. E., Hamilton, ON L8L 2X2, Canada, or at yusufs{at}mcmaster.ca.

Full Text of this Article

This article has been cited by other articles:

• Kim, D. H., Daskalakis, C., Silvestry, S. C., Sheth, M. P., Lee, A. N., Adams, S., Hohmann, S., Medvedev, S., Whellan, D. J. (2009). Aspirin and clopidogrel use in the early postoperative period following on-pump and off-pump coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. 138: 1377-1384 [Abstract] [Full Text]  
• Kushner, F. G., Hand, M., Smith, S. C. Jr, King, S. B. III, Anderson, J. L., Antman, E. M., Bailey, S. R., Bates, E. R., Blankenship, J. C., Casey, D. E. Jr, Green, L. A., Hochman, J. S., Jacobs, A. K., Krumholz, H. M., Morrison, D. A., Ornato, J. P., Pearle, D. L., Peterson, E. D., Sloan, M. A., Whitlow, P. L., Williams, D. O. (2009). 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 54: 2205-2241 [Full Text]  
• Maskrey, N., Underhill, J., Hutchinson, A., Shaughnessy, A., Slawson, D. (2009). Getting a better grip on research: A simple system that works. InnovAiT 2: 739-749 [Abstract] [Full Text]  
• Seet, R. C.-S., Chen, C. P.L. (2009). Optimizing Antiplatelet Therapy in High-Risk Patients With Atrial Fibrillation: Insights From Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A). Stroke 40: 3883-3885 [Full Text]  
• American College of Cardiology Foundation, , American Heart Association Task Force on Practice, , American Society of Echocardiography, , American Society of Nuclear Cardiology, , Heart Rhythm Society, , Society of Cardiovascular Anesthesiologists, , Society for Cardiovascular Angiography and Interve, , Society for Vascular Medicine, , Society for Vascular Surgery, , Fleisher, L. A., Beckman, J. A., Brown, K. A., Calkins, H., Chaikof, E. L., Fleischmann, K. E., Freeman, W. K., Froehlich, J. B., Kasper, E. K., Kersten, J. R., Riegel, B., Robb, J. F. (2009). 2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. J Am Coll Cardiol 54: e13-e118 [Full Text]  
• 2007 WRITING COMMITTEE MEMBERS, , Fleisher, L. A., Beckman, J. A., Brown, K. A., Calkins, H., Chaikof, E. L., Fleischmann, K. E., Freeman, W. K., Froehlich, J. B., Kasper, E. K., Kersten, J. R., Riegel, B., Robb, J. F. (2009). 2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 120: e169-e276 [Full Text]  
• Law, M. R., Soumerai, S. B., Adams, A. S., Majumdar, S. R. (2009). Costs and Consequences of Direct-to-Consumer Advertising for Clopidogrel in Medicaid. Arch Intern Med 169: 1969-1974 [Abstract] [Full Text]  
• Berger, J. S., Bhatt, D. L., Cannon, C. P., Chen, Z., Jiang, L., Jones, J. B., Mehta, S. R., Sabatine, M. S., Steinhubl, S. R., Topol, E. J., Berger, P. B. (2009). The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis.. J Am Coll Cardiol 54: 1935-1945 [Abstract] [Full Text]  
• Harrington, R. A., Stone, G. W., McNulty, S., White, H. D., Lincoff, A. M., Gibson, C. M., Pollack, C. V. Jr., Montalescot, G., Mahaffey, K. W., Kleiman, N. S., Goodman, S. G., Amine, M., Angiolillo, D. J., Becker, R. C., Chew, D. P., French, W. J., Leisch, F., Parikh, K. H., Skerjanec, S., Bhatt, D. L. (2009). Platelet Inhibition with Cangrelor in Patients Undergoing PCI. NEJM 0: NEJMoa0908628v3-1 [Abstract] [Full Text]  
• Bhatt, D. L., Lincoff, A. M., Gibson, C. M., Stone, G. W., McNulty, S., Montalescot, G., Kleiman, N. S., Goodman, S. G., White, H. D., Mahaffey, K. W., Pollack, C. V. Jr., Manoukian, S. V., Widimsky, P., Chew, D. P., Cura, F., Manukov, I., Tousek, F., Jafar, M. Z., Arneja, J., Skerjanec, S., Harrington, R. A., the CHAMPION PLATFORM Investigators, (2009). Intravenous Platelet Blockade with Cangrelor during PCI. NEJM 0: NEJMoa0908629v1-1 [Abstract] [Full Text]  
• Schulz, S., Schuster, T., Mehilli, J., Byrne, R. A., Ellert, J., Massberg, S., Goedel, J., Bruskina, O., Ulm, K., Schomig, A., Kastrati, A. (2009). Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J 30: 2714-2721 [Abstract] [Full Text]  
• RAYMOND, C., MENON, V. (2009). Dual antiplatelet therapy in coronary artery disease: A case-based approach. Cleveland Clinic Journal of Medicine 76: 663-670 [Abstract] [Full Text]  
• van Hattum, E. S., Algra, A., Lawson, J. A., Eikelboom, B. C., Moll, F. L., Tangelder, M. J.D. (2009). Bleeding Increases the Risk of Ischemic Events in Patients With Peripheral Arterial Disease. Circulation 120: 1569-1576 [Abstract] [Full Text]  
• Simon, D. I., Parikh, S. A. (2009). Hunting for the "Sweet Spot" in P2Y12 Receptor Blockade. J Am Coll Cardiol 54: 1447-1449 [Full Text]  
• Granger, C. B (2009). Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI. Evid. Based Med. 14: 154-154 [Full Text]  
• Aranki, S. F., Body, S. C. (2009). Antiplatelet agents used for early intervention in acute coronary syndrome: Myocardial salvage versus bleeding complications.. J. Thorac. Cardiovasc. Surg. 138: 807-810.e7 [Full Text]  
• Bjessmo, S. (2009). Increased rehospitalization rate after coronary bypass operation for acute coronary syndrome: a prospective study in 200 patients.. Ann. Thorac. Surg. 88: 1148-1152 [Abstract] [Full Text]  
• Kumar, A., Cannon, C. P. (2009). Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clin Proc. 84: 917-938 [Abstract] [Full Text]  
• Harjai, K J, Shenoy, C, Orshaw, P, Boura, J (2009). Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry. Heart 95: 1579-1586 [Abstract] [Full Text]  
• Marin, F., Gonzalez-Conejero, R., Capranzano, P., Bass, T. A., Roldan, V., Angiolillo, D. J. (2009). Pharmacogenetics in cardiovascular antithrombotic therapy.. J Am Coll Cardiol 54: 1041-1057 [Abstract] [Full Text]  
• Schomig, A. (2009). Ticagrelor -- Is There Need for a New Player in the Antiplatelet-Therapy Field?. NEJM 361: 1108-1111 [Full Text]  
• Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., Mahaffey, K. W., Scirica, B. M., Skene, A., Steg, P. G., Storey, R. F., Harrington, R. A., the PLATO Investigators, (2009). Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. NEJM 361: 1045-1057 [Abstract] [Full Text]  
• Bonaca, M. P., Steg, P. G., Feldman, L. J., Canales, J. F., Ferguson, J. J., Wallentin, L., Califf, R. M., Harrington, R. A., Giugliano, R. P. (2009). Antithrombotics in acute coronary syndromes.. J Am Coll Cardiol 54: 969-984 [Abstract] [Full Text]  
• Moukarbel, G. V., Signorovitch, J. E., Pfeffer, M. A., McMurray, J. J.V., White, H. D., Maggioni, A. P., Velazquez, E. J., Califf, R. M., Scheiman, J. M., Solomon, S. D. (2009). Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. Eur Heart J 30: 2226-2232 [Abstract] [Full Text]  
• Aberegg, S. K., O'Brien, J. M. Jr, Khoury, P., Patel, R., Arkes, H. R. (2009). The Influence of Treatment Effect Size on Willingness to Adopt a Therapy. Med Decis Making 29: 599-605 [Abstract]  
• Rahim, S. A., Mody, A., Pickering, J., Devereaux, P.J., Yusuf, S. (2009). Iatrogenic Adverse Events in the Coronary Care Unit. Circ Cardiovasc Qual Outcomes 2: 437-442 [Abstract] [Full Text]  
• Luckie, M, Khattar, R S, Fraser, D (2009). Non-cardiac surgery and antiplatelet therapy following coronary artery stenting. Heart 95: 1303-1308 [Abstract] [Full Text]  
• Wallentin, L. (2009). P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 30: 1964-1977 [Abstract] [Full Text]  
• Verstuyft, C., Simon, T., Kim, R. B. (2009). Personalized medicine and antiplatelet therapy: ready for prime time?. Eur Heart J 30: 1943-1963 [Full Text]  
• Ernest, C. S. II, Heathman, M. A., Wrishko, R. E. (2009). Prediction of Prasugrel Active Metabolite Concentrations From 2 Downstream Inactive Metabolite Concentrations Using Multilinear Regression Analysis. J Clin Pharmacol 49: 973-983 [Abstract] [Full Text]  
• Wrishko, R. E., Ernest, C. S. II, Small, D. S., Li, Y. G., Weerakkody, G. J., Riesmeyer, J. R., Macias, W. L., Rohatagi, S., Salazar, D. E., Antman, E. M., Wiviott, S. D., Braunwald, E., Ni, L. (2009). Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON-TIMI 38. J Clin Pharmacol 49: 984-998 [Abstract] [Full Text]  
• Jolly, S. S., Faxon, D. P., Fox, K. A.A., Afzal, R., Boden, W. E., Widimsky, P., Steg, P. G., Valentin, V., Budaj, A., Granger, C. B., Joyner, C. D., Chrolavicius, S., Yusuf, S., Mehta, S. R. (2009). Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.. J Am Coll Cardiol 54: 468-476 [Abstract] [Full Text]  
• Holmes, D. R. Jr, Kereiakes, D. J., Kleiman, N. S., Moliterno, D. J., Patti, G., Grines, C. L. (2009). Combining Antiplatelet and Anticoagulant Therapies.. J Am Coll Cardiol 54: 95-109 [Abstract] [Full Text]  
• Van de Werf, F. (2009). New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome?. Eur Heart J 30: 1695-1702 [Abstract] [Full Text]  
• Gao, C., Ren, C., Li, D., Li, L. (2009). Clopidogrel and aspirin versus clopidogrel alone on graft patency after coronary artery bypass grafting.. Ann. Thorac. Surg. 88: 59-62 [Abstract] [Full Text]  
• Esposito, R. A. (2009). Invited commentary.. Ann. Thorac. Surg. 88: 62-63 [Full Text]  
• Ho, P. M., Rumsfeld, J. S., Wang, L. (2009). Adverse Outcomes Associated With Use of Proton Pump Inhibitors and Clopidogrel--Reply. JAMA 302: 31-31 [Full Text]  
• Schneider-Lindner, V., Filion, K. B., Brophy, J. M. (2009). Adverse Outcomes Associated With Use of Proton Pump Inhibitors and Clopidogrel. JAMA 302: 29-30 [Full Text]  
• Wilson, J M (2009). Diagnosis and treatment of acquired coronary artery disease in adults. Postgrad. Med. J. 85: 364-365 [Abstract] [Full Text]  
• O'Kane, P., Xie, L., Liu, Z., Queen, L., Jackson, G., Ji, Y., Ferro, A. (2009). Aspirin acetylates nitric oxide synthase type 3 in platelets thereby increasing its activity. Cardiovasc Res 83: 123-130 [Abstract] [Full Text]  
• Bhindi, R., Figtree, G. A., Edwards, J. L., Brereton, R. J.L., Misfeld, M., Ross, D. E., Shil, A. B., Aung, T., Strohm, M. P., Bonvini, R. F., Rapp, F., Roffi, M., Serruys, P. W., Mohr, F. W., the SYNTAX Investigators, (2009). Percutaneous coronary intervention versus coronary-artery bypass grafting.. NEJM 360: 2672-2673 [Full Text]  
• APPRAISE Steering Committee and Investigators, (2009). Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial. Circulation 119: 2877-2885 [Abstract] [Full Text]  
• Pogue, J., Walter, S. D, Yusuf, S. (2009). Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. Clin Trials 6: 239-251 [Abstract]  
• Diener, H.-C., Weimar, C. (2009). Update of secondary stroke prevention. Nephrol Dial Transplant 24: 1718-1724 [Full Text]  
• To, A. C.Y., Armstrong, G., Zeng, I., Webster, M. W.I. (2009). Noncardiac Surgery and Bleeding After Percutaneous Coronary Intervention. Circ Cardiovasc Interv 2: 213-221 [Abstract] [Full Text]  
• Ebrahimi, R., Dyke, C., Mehran, R., Manoukian, S. V., Feit, F., Cox, D. A., Gersh, B. J., Ohman, E. M., White, H. D., Moses, J. W., Ware, J. H., Lincoff, A. M., Stone, G. W. (2009). Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.. J Am Coll Cardiol 53: 1965-1972 [Abstract] [Full Text]  
• Price, M. J. (2009). Bedside Evaluation of Thienopyridine Antiplatelet Therapy. Circulation 119: 2625-2632 [Full Text]  
• The ACTIVE Investigators, (2009). Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. NEJM 360: 2066-2078 [Abstract] [Full Text]  
• Smout, J., Stansby, G. (2009). Surgery and antiplatelet agents: what are the risks?. Clin Risk 15: 101-105 [Full Text]  
• Cleanthis, M, Flather, M. (2009). The dangers of stopping clopidogrel perioperatively: a cardiologist's perspective. Clin Risk 15: 106-108 [Full Text]  
• Chen, B. L., Chen, Y., Tu, J. H., Li, Y. L., Zhang, W., Li, Q., Fan, L., Tan, Z. R., Hu, D. L., Wang, D., Wang, L. S., OuYang, D. S., Zhou, H. H. (2009). Clopidogrel Inhibits CYP2C19-Dependent Hydroxylation of Omeprazole Related to CYP2C19 Genetic Polymorphisms. J Clin Pharmacol 49: 574-581 [Abstract] [Full Text]  
• Ford, N. F. (2009). Clopidogrel Resistance: Pharmacokinetic or Pharmacogenetic?. J Clin Pharmacol 49: 506-512 [Abstract] [Full Text]  
• Blasco-Colmenares, E., Perl, T. M., Guallar, E., Baumgartner, W. A., Conte, J. V., Alejo, D., Pastor-Barriuso, R., Sharrett, A. R., Faraday, N. (2009). Aspirin Plus Clopidogrel and Risk of Infection After Coronary Artery Bypass Surgery. Arch Intern Med 169: 788-795 [Abstract] [Full Text]  
• Desai, N. R., Mega, J. L., Jiang, S., Cannon, C. P., Sabatine, M. S. (2009). Interaction between cigarette smoking and clinical benefit of clopidogrel.. J Am Coll Cardiol 53: 1273-1278 [Abstract] [Full Text]  
• Chua, D., Ignaszewski, A. (2009). Clopidogrel in acute coronary syndromes. BMJ 338: b1180-b1180 [Full Text]  
• Mehilli, J., Kastrati, A., Schulz, S., Frungel, S., Nekolla, S. G., Moshage, W., Dotzer, F., Huber, K., Pache, J., Dirschinger, J., Seyfarth, M., Martinoff, S., Schwaiger, M., Schomig, A., for the Bavarian Reperfusion Alternatives Evaluati, (2009). Abciximab in Patients With Acute ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Clopidogrel Loading: A Randomized Double-Blind Trial. Circulation 119: 1933-1940 [Abstract] [Full Text]  
• Subherwal, S., Bach, R. G., Chen, A. Y., Gage, B. F., Rao, S. V., Newby, L. K., Wang, T. Y., Gibler, W. B., Ohman, E. M., Roe, M. T., Pollack, C. V. Jr, Peterson, E. D., Alexander, K. P. (2009). Baseline Risk of Major Bleeding in Non-ST-Segment-Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score. Circulation 119: 1873-1882 [Abstract] [Full Text]  
• Jolly, S. S., Pogue, J., Haladyn, K., Peters, R. J.G., Fox, K. A.A., Avezum, A., Gersh, B. J., Rupprecht, H. J., Yusuf, S., Mehta, S. R. (2009). Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur Heart J 30: 900-907 [Abstract] [Full Text]  
• Schiele, F., Meneveau, N., Seronde, M. F., Descotes-Genon, V., Oettinger, J., Ecarnot, F., Bassand, J.-P., on behalf of the 'Reseau de Cardiologie de Franche, (2009). Changes in management of elderly patients with myocardial infarction. Eur Heart J 30: 987-994 [Abstract] [Full Text]  
• Ruiz-Nodar, J. M., Marin, F., Sanchez-Paya, J., Hurtado, J. A., Valencia-Martin, J., Manzano-Fernandez, S., Roldan, V., Perez-Andreu, V., Sogorb, F., Valdes, M., Lip, G. Y.H. (2009). Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. Eur Heart J 30: 932-939 [Abstract] [Full Text]  
• Angiolillo, D. J. (2009). Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions. Diabetes Care 32: 531-540 [Full Text]  
• Potsis, T. Z., Katsouras, C., Goudevenos, J. A. (2009). Avoiding and Managing Bleeding Complications in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. ANGIOLOGY 60: 148-158 [Abstract]  
• Seddighzadeh, A., Wolf, A. T., Parasuraman, S., Shetty, R., Vallurupalli, N., Reddy, S., Goldhaber, S. Z. (2009). Gastrointestinal Complications After 3 Months of Dual Antiplatelet Therapy for Drug-eluting Stents as Assessed by Wireless Capsule Endoscopy. CLIN APPL THROMB HEMOST 15: 171-176 [Abstract]  
• ALEXANDER, J. H. (2009). The current state of antiplatelet therapy in acute coronary syndromes: The data and the real world. Cleveland Clinic Journal of Medicine 76: S16-S23 [Abstract] [Full Text]  
• Smyth, S. S., Woulfe, D. S., Weitz, J. I., Gachet, C., Conley, P. B., Goodman, S. G., Roe, M. T., Kuliopulos, A., Moliterno, D. J., French, P. A., Steinhubl, S. R., Becker, R. C., for the 2008 Platelet Colloquium Participants, (2009). G-Protein-Coupled Receptors as Signaling Targets for Antiplatelet Therapy. Arterioscler. Thromb. Vasc. Bio. 29: 449-457 [Abstract] [Full Text]  
• Collyer, T. C., Gray, D. J., Sandhu, R., Berridge, J., Lyons, G. (2009). Assessment of platelet inhibition secondary to clopidogrel and aspirin therapy in preoperative acute surgical patients measured by Thrombelastography(R) Platelet MappingTM. Br J Anaesth 102: 492-498 [Abstract] [Full Text]  
• Lau, W. C., Gurbel, P. A. (2009). The drug-drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180: 699-700 [Full Text]  
• Jeong, Y. H., Lee, S.-W., Choi, B.-R., Kim, I.-S., Seo, M.-K., Kwak, C. H., Hwang, J.-Y., Park, S.-W. (2009). Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study.. J Am Coll Cardiol 53: 1101-1109 [Abstract] [Full Text]  
• Juurlink, D. N., Gomes, T., Ko, D. T., Szmitko, P. E., Austin, P. C., Tu, J. V., Henry, D. A., Kopp, A., Mamdani, M. M. (2009). A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180: 713-718 [Abstract] [Full Text]  
• Lopes, R. D., Alexander, K. P., Manoukian, S. V., Bertrand, M. E., Feit, F., White, H. D., Pollack, C. V. Jr, Hoekstra, J., Gersh, B. J., Stone, G. W., Ohman, E. M. (2009). Advanced Age, Antithrombotic Strategy, and Bleeding in Non-ST-Segment Elevation Acute Coronary Syndromes: Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial. J Am Coll Cardiol 53: 1021-1030 [Abstract] [Full Text]  
• Ho, P. M., Maddox, T. M., Wang, L., Fihn, S. D., Jesse, R. L., Peterson, E. D., Rumsfeld, J. S. (2009). Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome. JAMA 301: 937-944 [Abstract] [Full Text]  
• Budaj, A., Eikelboom, J. W., Mehta, S. R., Afzal, R., Chrolavicius, S., Bassand, J.-P., Fox, K. A.A., Wallentin, L., Peters, R. J.G., Granger, C. B., Joyner, C. D., Yusuf, S., on behalf of OASIS 5 Investigators, (2009). Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 30: 655-661 [Abstract] [Full Text]  
• Hopkins, J., Limacher, M. (2009). The Role of Aspirin in Cardiovascular Disease Prevention in Women. AMERICAN JOURNAL OF LIFESTYLE MEDICINE 3: 123-134 [Abstract]  
• Ryan, J., Linde-Zwirble, W., Engelhart, L., Cooper, L., Cohen, D. J. (2009). Temporal Changes in Coronary Revascularization Procedures, Outcomes, and Costs in the Bare-Metal Stent and Drug-Eluting Stent Eras: Results From the US Medicare Program. Circulation 119: 952-961 [Abstract] [Full Text]  
• Kuliczkowski, W., Witkowski, A., Polonski, L., Watala, C., Filipiak, K., Budaj, A., Golanski, J., Sitkiewicz, D., Pregowski, J., Gorski, J., Zembala, M., Opolski, G., Huber, K., Arnesen, H., Kristensen, S. D., De Caterina, R. (2009). Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 30: 426-435 [Abstract] [Full Text]  
• Cohen, M. (2009). Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care. Mayo Clin Proc. 84: 149-160 [Abstract] [Full Text]  
• Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Meneveau, N., Steg, P. G., Ferrieres, J., Danchin, N., Becquemont, L., the French Registry of Acute ST-Elevation and Non-, (2009). Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. NEJM 360: 363-375 [Abstract] [Full Text]  
• Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E., Sabatine, M. S. (2009). Cytochrome P-450 Polymorphisms and Response to Clopidogrel. NEJM 360: 354-362 [Abstract] [Full Text]  
• Cacoub, P. P., Bhatt, D. L., Steg, P.G., Topol, E. J., Creager, M. A., for the CHARISMA Investigators, (2009). Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 0: ehn534v1-10 [Abstract] [Full Text]